Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$374.50M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$376.01M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
Market Cap
$369.50M
Gross Margin
95.50%
TTM Avg
97.75%
3Y Avg
98.88%
5Y Avg
1.50%
Market Cap
$380.37M
Gross Margin
69.59%
TTM Avg
67.69%
3Y Avg
68.42%
5Y Avg
70.65%
Market Cap
$361.64M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$359.53M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$355.43M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $374.50M | 0.00% | 0.00% | 0.00% | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | 25.47% | 27.02% | 15.55% | 5.84% |
| Zura Bio Limited (ZURA)vs › | $376.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | 95.50% | 97.75% | 98.88% | 1.50% |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | 69.59% | 67.69% | 68.42% | 70.65% |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | 88.09% | 73.91% | 64.55% | 70.68% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 99.87% | 100.00% | 100.00% | 83.33% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 93.73% | 92.44% | 93.34% | 78.89% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 0.00% | 50.00% | 75.00% | 66.67% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 57.21% | 58.46% | 59.89% | 60.54% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -32.62% |
